Strides Pharma Q2FY27 Revenue ₹14,297m, Up 17% YoY; EBITDA ₹2,509m
Strides Pharma Science Limited reported Q2FY27 revenue of ₹14,297 million, up 17% YoY. Ex-US Markets grew 31% YoY to ₹6,963 million. EBITDA increased 8.4% YoY to ₹2,509 million. Operational PAT rose 11.5% YoY to ₹1,358 million. Mr. Biren Gabhawala was appointed as an Independent Director.
The announcement details significant financial performance improvements, including record EBITDA and strong revenue growth, which are material to investors. The appointment of a new director also adds to the impact.
The company reported strong year-on-year revenue and EBITDA growth, crossing significant milestones. The Ex-US markets showed particularly strong performance, and a new independent director was appointed, indicating positive strategic and governance developments.
Strides Pharma Science Limited announced its consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a strong Q2FY27 performance with revenue reaching ₹14,297 million, marking a 17.1% year-on-year growth. This growth was primarily driven by a robust 31% YoY increase in Ex-US Markets revenue, which amounted to ₹6,963 million, surpassing the US business revenue for the first time in a quarter. The US business contributed ₹6,855 million, showing a 9% YoY growth and saw the launch of three new products.
EBITDA for the quarter rose by 8.4% YoY to ₹2,509 million, crossing the ₹2,500 million mark for the first time in a quarter, despite increased input material and freight costs. The EBITDA margin stood at 17.6%. Operational Profit After Tax (PAT) increased by 11.5% YoY to ₹1,358 million, with an operational EPS of ₹14.7. Reported PAT grew by 2.0% YoY to ₹1,341 million, resulting in a reported EPS of ₹14.2.
For the half-year ended September 30, 2026 (H1FY27), revenue grew by 15.1% YoY to ₹26,951 million, and EBITDA increased by 6.9% YoY to ₹4,807 million. Reported PAT for H1FY27 surged by 26.4% YoY to ₹2,996 million.
MD & Group CEO, Badree Komandur, commented that the diversification strategy is proving effective with Ex-US Markets leading growth. He also noted that Net Debt increased by ₹2,114 million during H1FY27 due to an elongated cash-to-cash cycle and higher inventory. The company expects the Net Debt to EBITDA ratio to stabilize by the end of the year. The company also announced the appointment of Mr. Biren Gabhawala as an Independent Director to its Board.
What to do with a filing like this
Strides Pharma Science Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Strides Pharma Science Limited. Read the original for the full detail.